ERBB2 and breast carcinoma: A cohort of 31 patients with post-CDK4/6 inhibitor HR+/HER2- advanced breast cancer received CT7001 in combination with fulvestrant, resulting in 3 patients achieving PR with a CBR of 36.0% (9/25) [106].